Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by R. Bavrasad
Total Records ( 2 ) for R. Bavrasad
  R. Bavrasad , N. Sharaf al-Din Zadeh , S.E.M. Nejad , N.M. Nasab and F. Rahim
  This study was accompanied due to high mortality and morbidity in these patients trying to find more useful treatment. A total 54 patient with ICH Next to stroke referred to Ahwaz Golestan hospital from Jul 2008 to 2009 were selected. Patients were randomly assigned to receive a single intravenous dose of 40 μg kg -1 of rFVIIa or placebo. The performance by a clinical neurologist and based on the international ranking (Rankin's scale) on the first day of hospitalization and 90 days after discharge was evaluated. There was no significant difference in mean arterial blood pressure between placebo and patient groups. Percentage increase in both the second day of bleeding volume in the patient and placebo groups was 2.35 and 0.35%, respectively. The total difference between the first day and third day in the patient and placebo group was -7.76- and -2.99%, respectively. Patients with MAP value of more than 120 mmHg, showed a significant response to rFVIIa treatment. Recombinant activated factor VII has the potential to limit or even halt the progression of bleeding in brain hemorrhagic patients that would otherwise place growing pressure on the brain. As such, these data suggest that the use of rFVIIa holds promise in the setting of non-surgical intracranial bleeding. Whether this usage will have a positive impact on the neurological outcome lies in a future prospective clinical trial whose planning is underway.
  R. Bavrasad , S.E.M. Nejad , A.R. Yarahmadi , S.I. Sajedi and F. Rahim
  This randomized-double-blind aimed to show the effect of middle dose of topiramate and monitor the sodium valproate as a treatment quite acceptable in migraine prophylaxis as well as compare health and treatment effects in reducing both frequency and the severity of headache. Seventy-three females patients filled questionnaire based on the migraine disability assessment score (MIDAS) in the beginning and end of the study. Frequency, severity, duration of headache attacks and symptoms of drug in each of the patients are listed in his file. The effects of middle dose of topiramate (50-75 mg) and sodium valproate (400-600 mg) in the prevention of migraine headache was compared. Out of the 73 patients three cases were excluded due to unwanted and adverse events. Although, both drugs have been successful in reducing headache frequency more than 50% within the study, but there was no significant difference. The MIDAS score in topiramate group reduced more than the group receiving valproate sodium, which indicates changes, was statistically significant in both groups before treatment. The most common complications recorded in the group receiving topiramate were, paresthesia followed by weight loss, drowsiness and dizziness in topiramate group. While, the most common complications recorded in the group receiving sodium valproate were, drowsiness, weight gain, hair loss, nausea and Tremor. This trial demonstrates that topiramate significantly reduced mean monthly migraine and was a safe and well-tolerated preventive therapy in this group of subjects with migraine, a therapeutic area in which profound clinical needs exist.
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility